At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 222 enrolled
Drug / intervention
XL184drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse
In Brief
A Phase 2 clinical trial evaluating XL184 for Glioblastoma Multiforme. Completed, enrolled 222 participants across 8 sites.
Detailed Summary
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma Multiforme
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJun 2008
Primary CompletionJun 2012
Study CompletionDec 2012
TodayJul 2026
First PostedJun 24, 2008
Enrollment StartMay 1, 2008
Primary CompletionJun 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 18.0 years ago
Interventions
XL184drug
Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing